Life Sciences

With a busy 2017, we've compiled the biopharma partnering and M&A deal activity so far this year (through May).

Quickly see what collaborations have been forged in 2017 in the various therapeutic areas, and drill down for more detail by clicking the hyperlinks to news releases.

This webinar presents an introduction to the key concepts and most common methodologies used to evaluate life sciences businesses and assets. Get an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital and present value.

 

If you want to find ways to expand your biomedical startup using NIH funding, you won't want to miss this guide! Stephanie Fertig and Kory Hallett from the National Institutes of Health (NIH) give an overview of SBIR and STTR Small Business programs at the NIH.

Based on the common questions we get from virtual data room users, we’re hosting this 30-minute webinar to make sure you get the most out of your virtual data room. Gain tips and tricks that will allow you to save hours and increase efficiency.

This white paper discusses the role of non-immuno-oncology treatments for cancer in a world where immuno-oncology is playing a greater role...

This white paper is a continuation of the first, entitled "Must-Know Finance Concepts for Life Sciences Valuations." It goes into more detail on the key concepts and most common methodologies used to evaluate life sciences assets....

Four panelists from leading global pharmaceutical companies and research organizations discussed theories of cancer, favorite targets and modalities, the impact of reimbursement, deal types, and more. 

There are few people in the world like James Greenwood, BIO CEO, who have as much experience and expertise in successfully connecting biotech companies with large pharma. We recently had the opportunity to sit down with him and pick his brain about the future of biopharma partnering.

GlaxoSmithKline CEO Andrew Witty once commented on the high cost of drug development, saying, “If you stop failing so often, you massively reduce the cost of drug development.”

So, why do clinical trials fail, and what can be done about it?

Although we have long known about the existence of microbes—the tiny bacteria, fungi and archaea that live all around us, on us, and in us—interest in how the microbiome might impact human therapeutics has become a hot topic in research only recently...

When entering due diligence, it's important to know what information to share and when to share it ensure a timely process. This excel-based due diligence checklist - which is easy to upload to a virtual data room - is designed to make sure you have the information you need for a streamlined due diligence process. 

Gain a high-level overview of the main biopharma partnering deals of 2016, along with links to news articles relating to each deal. Quickly see what collaborations have been forged in the various therapeutic areas.

Due diligence and finance experts from global pharmaceutical companies join legal advisors and consultants to share their expertise in a lively discussion on the issues that arise during due diligence.

 

Learn how Cure SMA leveraged a ShareVault virtual data room to advance one of the very first drug programs focused on finding a cure for Spinal Muscular Atrophy.

Using suppliers is an excellent way to get access to skills and technology that aren’t available internally. However, using suppliers may also create wasted time and effort on the part of the company and the supplier. After both working with suppliers and being a supplier, Maren Nelson has learned...